ClinicalTrials.gg
CompletedNCT00468546Updated Oct 25, 2016Results posted

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

A Phase 3 interventional study of MabThera/Rituxan and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 115 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-10-25.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
5th of 63
520 · median 159
Started
2003
with 1 other
Phase 3
27 of 63
1 open now
Registered
14th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 2 that started in 2003, is one of 27 in phase 3, and was the 14th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants 18-80 years of age with active RA for at least 6 months;
  • Received treatment for RA on an outpatient basis and experienced an inadequate response or intolerance to treatment with at least 1 anti-TNF alpha therapy (etanercept, infliximab or adalimumab);
  • Must have received MTX for a minimum of 12 weeks, with the last 4 weeks, prior to screening at a stable dose;
  • Participants with swollen joint count (SJC) and tender joint count (TJC) of at least 8 joints at screening and at randomization;
  • Radiographic evidence of at least 1 joint with a definite erosion due to RA;
  • Participants of must be using reliable methods.

Exclusion criteria

Exclusion Criteria:

  • Bone or joint surgery within 8 weeks prior to screening or joint surgery planned within 24 weeks of randomization;
  • Class IV functional status of RA;
  • Previous treatment within 6 months with intravenous gamma globulin, or the Prosorba column;
  • Intraarticular or parenteral within 4 weeks prior to screening visit;
  • With a within 4 weeks prior to randomization;
  • Previous treatment with rituximab or other cell-depleting therapies;
  • Concurrent treatment with any disease-modifying anti-rheumatic drug (except for MTX) or any anti-TNF alfa factor or other biologic therapy;
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies;
  • Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders;
  • Known to receiving rituximab;
  • Known active bacterial, viral, fungal, mycobacterial or other infection;
  • History of recurrent significant infection or history of recurrent bacterial infections;
  • Primary or secondary immunodeficiency (history of, or currently active);
  • History of cancer, including solid tumors and hematologic (except basal cell or squamous cell carcinoma of the skin that have been excised and cured);
  • Women who are pregnant or breast-feeding;
  • History of alcohol, drug or chemical abuse within 6 months prior to screening;
  • Neuropathies and neurovasculopathies which might interfere with pain evaluation;
  • Participants with poor peripheral venous access;
  • Intolerance or contraindications to oral or intravenous corticosteroids.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
520 participants (actual)

Study arms

  • Placebo comparator
    Placebo Plus Methotrexate

    Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.

    Drug: Methotrexate · Other: Placebo

  • Experimental
    Rituximab plus Methotrexate

    Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.

    Drug: MabThera/Rituxan · Drug: Methotrexate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With American College of Rheumatology 20 Response at Week 24

    American College of Rheumatology (ACR) 20 response is defined as \>= 20% improvement (reduction) in score compared with baseline for both tender joint count (TJC)-68 joints and swollen joint count (SJC)-66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) ranging from score 0 (no pain) to 100 (unbearable pain); Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging score 0 (no disease activity) to 100 (maximum disease activity); Health Assessment Questionnaire (HAQ):8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do) for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR).

    Time frame: Week 24

Secondary outcomes

  1. Number of Participants With an ACR 50 Response at Week 24

    ACR 50 response is defined as a \>= 50% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.

    Time frame: Week 24

  2. Number of Participants With ACR 70 Response at Week 24

    ACR 70 response is defined as a \>= 70% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.

    Time frame: Week 24

  3. Mean Change From Baseline in Disease Activity Score of 28 Joints at Week 24

    The disease activity score (DAS28) is an evaluation index of rheumatoid arthritis. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC-28 joints, 2. SJC -28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health (global health \[GH\]) status expressed by a VAS (0 \[no disease activity\] to 100 \[maximum disease activity\]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. Change from Baseline = difference between the score at Week 24 and the score at Baseline.

    Time frame: From Baseline (Day 1) to Week 24

  4. Percentage of Participants With DAS28 Low Disease Activity and DAS28 Remission at Week 24

    The DAS28 is an evaluation index of RA. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC- 28 joints, 2. SJC- 28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health status (GH) expressed by a visual analogue scale VAS (0 \[no disease activity\] to 100 \[maximum disease activity\]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10. A participant was categorized as having low disease activity, if participant's DAS28 score was \<= 3.2, and was categorized as having clinical remission if participant's DAS28 score was \< 2.6.

    Time frame: Week 24

  5. Number of Participants With Good, Moderate, or no European League Against Rheumatism Responses at Week 24

    European League Against Rheumatism (EULAR) response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999). The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. At a given visit, participants with a DAS28 score of \< 3.2 are considered good responders if the change from baseline in their DAS28 score is \>1.2. Participants with a DAS28 score \>= 3.2 to 5.1 are considered moderate responders if the change from baseline in their DAS28 score is \<=1.2 to \>=0.6. Participants with DAS28 score \>5.1 are considered non-responders if the change from baseline in their DAS28 score is \<=1.2 to \>=0.6.

    Time frame: Week 24

  6. Percentage Change From Baseline in the ACR Core Set (SJC, TJC, Patient's and Physician's Global Assessments, Health Assessment Questionnaire, Pain, C-Reactive Protein, and Erythrocyte Sedimentation Rate) Score

    Percentage change in the scores of the following parameters of ACR core set relative to respective baseline scores in both study arms was analyzed : SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS \[0 = no disease activity to 100 = maximum disease activity\]), HAQ (based on HAQ disability index \[HAQDI\]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain), CRP concentration, and ESR.

    Time frame: From Baseline (Day 1) to Week 24

  7. Mean Change From Baseline of Short Form 36 Total Scores at Week 24

    The Short Form (SF)-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Transforming and standardizing these domains leads to the calculation of the physical component summary and mental component summary measures. Scores on each item were summed and averaged (range 0 \[worst\] to 100 \[best\]); increase in score from baseline indicated improvement. Change from Baseline = difference between the score at Week 24 and the score at Baseline.

    Time frame: From Baseline (Day 1) to Week 24

  8. Number of Participants With Categorical Change From Baseline in the Physical Component Scores of SF-36

    The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on physical component were summed and averaged (range 0 \[worst\] to 100 \[best\]); If participants' had shown change from baseline in physical health component score \>5.42, it was considered as improved; score between -5.42 to 5.42 was considered as unchanged, and score \< -5.42 was considered as worsened. Change from Baseline = difference between the score of physical component at Week 24 and the score at Baseline.

    Time frame: From Baseline (Day 1) to Week 24

  9. Number of Participants With Change From Baseline in the Mental Component Scores of SF-36

    The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on mental component were summed and averaged (range = 0 \[worst\]-100 \[best\]); increase from baseline indicated improvement. If participants' had shown change from baseline in mental health score \>6.33, it was considered as improved; scores between -6.33 to 6.33 was considered unchanged, and score \<-6.33 was considered as worsened. Change from Baseline = difference between the mental component score at Week 24 and the score at Baseline.

    Time frame: From Baseline (Day 1) to Week 24

  10. Mean Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score, Genant-modified Sharp Total Score, and Erosion Score

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290. For all the three radiograph assessment, the minimum score is 0. A higher score indicates more damage and a negative change score indicates improvement. The change in score is to be calculated as: Change from Baseline = difference between the score at Weeks 24, 56, or 104 and the score at Baseline.

    Time frame: From Baseline (Day 1) to Weeks (W) 24, 56, and 104

  11. Percentage of Participants Without Erosive Progression

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage and negative change score indicates improvement.

    Time frame: Up to Week 104

07

Results

Posted Oct 25, 2016

Participant flow

A total of 520 participants were enrolled in the study conducted from 02 May 2003 and 12 July 2012 in 11 countries.

Week 24 Analysis
Participant flow — Week 24 Analysis
MilestonePlacebo Plus MethotrexateRituximab Plus Methotrexate
Started208308
Completed111253
Not completed9755
Withdrew: Lack of efficacy8337
Withdrew: Refused treatment55
Withdrew: Adverse event18
Withdrew: Failure to return34
Withdrew: Rescue therapy20
Withdrew: Incorrect diagnosis and treatment01
Withdrew: Due to clinical hold10
Withdrew: Went onto rescue therapy10
Withdrew: Participant unblinded (clinical hold)10
Week 24 to Week 104 Analysis
Participant flow — Week 24 to Week 104 Analysis
MilestonePlacebo Plus MethotrexateRituximab Plus Methotrexate
Started208308
Completed10383
Not completed105225
Withdrew: Adverse event25
Withdrew: Death10
Withdrew: Lack of efficacy312
Withdrew: Protocol violation02
Withdrew: Refused treatment47
Withdrew: Failure to return12
Withdrew: Movement into re-treatment study77183
Withdrew: Other1714

Outcome measures

PrimaryNumber of Participants With American College of Rheumatology 20 Response at Week 24

American College of Rheumatology (ACR) 20 response is defined as \>= 20% improvement (reduction) in score compared with baseline for both tender joint count (TJC)-68 joints and swollen joint count (SJC)-66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) ranging from score 0 (no pain) to 100 (unbearable pain); Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging score 0 (no disease activity) to 100 (maximum disease activity); Health Assessment Questionnaire (HAQ):8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do) for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR).

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With American College of Rheumatology 20 Response at Week 24
participantsPlacebo Plus MethotrexateRituximab Plus Methotrexate
Number of Participants With American College of Rheumatology 20 Response at Week 2436153
SecondaryNumber of Participants With an ACR 50 Response at Week 24

ACR 50 response is defined as a \>= 50% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With an ACR 50 Response at Week 24
participantsPlacebo Plus MethotrexateRituximab Plus Methotrexate
Number of Participants With an ACR 50 Response at Week 241180
SecondaryNumber of Participants With ACR 70 Response at Week 24

ACR 70 response is defined as a \>= 70% improvement (reduction) in score compared with baseline for both TJC -68 joints and SJC -66 joints, as well as for 3 of the additional 5 ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS ranging from score '0'=no pain to score '100'=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS ranging from score '0'=no disease activity to score '100'=maximum disease activity; HAQ : Health Assessment Questionnaire (HAQ):which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst); and acute-phase reactant, either CRP or ESR.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With ACR 70 Response at Week 24
participantsPlacebo Plus MethotrexateRituximab Plus Methotrexate
Number of Participants With ACR 70 Response at Week 24337
SecondaryMean Change From Baseline in Disease Activity Score of 28 Joints at Week 24

The disease activity score (DAS28) is an evaluation index of rheumatoid arthritis. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC-28 joints, 2. SJC -28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health (global health \[GH\]) status expressed by a VAS (0 \[no disease activity\] to 100 \[maximum disease activity\]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. Change from Baseline = difference between the score at Week 24 and the score at Baseline.

Time frame:
From Baseline (Day 1) to Week 24
Reported as:
Mean · units on a scale
Mean Change From Baseline in Disease Activity Score of 28 Joints at Week 24
units on a scalePlacebo Plus MethotrexateRituximab Plus Methotrexate
Mean Change From Baseline in Disease Activity Score of 28 Joints at Week 24-0.4 ± 1.17-1.9 ± 1.60
SecondaryPercentage of Participants With DAS28 Low Disease Activity and DAS28 Remission at Week 24

The DAS28 is an evaluation index of RA. The DAS28 applies a mathematical formula based on the following parameters: 1. TJC- 28 joints, 2. SJC- 28 joints, 3. ESR or CRP measurement, 4. Participant's judgement on his own overall health status (GH) expressed by a visual analogue scale VAS (0 \[no disease activity\] to 100 \[maximum disease activity\]). The mathematical formula is 0.56 × √28TJC + 0.28 × √28SJC + 0.7 x loge ESR + 0.014 × GH. The DAS28 scale ranges from score of 0 to 10. A participant was categorized as having low disease activity, if participant's DAS28 score was \<= 3.2, and was categorized as having clinical remission if participant's DAS28 score was \< 2.6.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28 Low Disease Activity and DAS28 Remission at Week 24
percentage of participantsPlacebo Plus MethotrexateRituximab Plus Methotrexate
Low disease activity215
Remission09
SecondaryNumber of Participants With Good, Moderate, or no European League Against Rheumatism Responses at Week 24

European League Against Rheumatism (EULAR) response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999). The DAS28 scale ranges from score of 0 to 10, where lower scores indicate best disease control and higher scores indicate worsening of disease. At a given visit, participants with a DAS28 score of \< 3.2 are considered good responders if the change from baseline in their DAS28 score is \>1.2. Participants with a DAS28 score \>= 3.2 to 5.1 are considered moderate responders if the change from baseline in their DAS28 score is \<=1.2 to \>=0.6. Participants with DAS28 score \>5.1 are considered non-responders if the change from baseline in their DAS28 score is \<=1.2 to \>=0.6.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With Good, Moderate, or no European League Against Rheumatism Responses at Week 24
participantsPlacebo Plus MethotrexateRituximab Plus Methotrexate
No response157105
Moderate response40149
Good response444
SecondaryPercentage Change From Baseline in the ACR Core Set (SJC, TJC, Patient's and Physician's Global Assessments, Health Assessment Questionnaire, Pain, C-Reactive Protein, and Erythrocyte Sedimentation Rate) Score

Percentage change in the scores of the following parameters of ACR core set relative to respective baseline scores in both study arms was analyzed : SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS \[0 = no disease activity to 100 = maximum disease activity\]), HAQ (based on HAQ disability index \[HAQDI\]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain), CRP concentration, and ESR.

Time frame:
From Baseline (Day 1) to Week 24
Reported as:
Mean · percent change
Percentage Change From Baseline in the ACR Core Set (SJC, TJC, Patient's and Physician's Global Assessments, Health Assessment Questionnaire, Pain, C-Reactive Protein, and Erythrocyte Sedimentation Rate) Score
percent changePlacebo Plus MethotrexateRituximab Plus Methotrexate
SJC (66)-5.6 ± 59.19-43.0 ± 52.65
SJC (28)-7.1 ± 55.35-41.3 ± 52.77
TJC (68)7.2 ± 144.58-41.8 ± 52.39
TJC (28)15.7 ± 195.94-42.0 ± 63.47
Physician's global assessment-4.2 ± 47.23-40.8 ± 39.31
Patient's global assessment-3.1 ± 44.01-25.4 ± 117.90
Patient's pain assessment2.8 ± 55.61-23.8 ± 131.59
HAQ-2.0 ± 30.46-24.3 ± 34.92
CRP80.0 ± 452.94-36.3 ± 80.3
ESR11.4 ± 95.95-29.3 ± 59.92
SecondaryMean Change From Baseline of Short Form 36 Total Scores at Week 24

The Short Form (SF)-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Transforming and standardizing these domains leads to the calculation of the physical component summary and mental component summary measures. Scores on each item were summed and averaged (range 0 \[worst\] to 100 \[best\]); increase in score from baseline indicated improvement. Change from Baseline = difference between the score at Week 24 and the score at Baseline.

Time frame:
From Baseline (Day 1) to Week 24
Reported as:
Mean · units on a scale
Mean Change From Baseline of Short Form 36 Total Scores at Week 24
units on a scalePlacebo Plus MethotrexateRituximab Plus Methotrexate
Physical score0.9 ± 5.655.8 ± 8.47
Mental health score1.3 ± 9.434.7 ± 11.75
SecondaryNumber of Participants With Categorical Change From Baseline in the Physical Component Scores of SF-36

The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on physical component were summed and averaged (range 0 \[worst\] to 100 \[best\]); If participants' had shown change from baseline in physical health component score \>5.42, it was considered as improved; score between -5.42 to 5.42 was considered as unchanged, and score \< -5.42 was considered as worsened. Change from Baseline = difference between the score of physical component at Week 24 and the score at Baseline.

Time frame:
From Baseline (Day 1) to Week 24
Reported as:
Number · participants
Number of Participants With Categorical Change From Baseline in the Physical Component Scores of SF-36
participantsPlacebo Plus MethotrexateRituximab Plus Methotrexate
Improved25141
Unchanged158136
Worsened1417
SecondaryNumber of Participants With Change From Baseline in the Mental Component Scores of SF-36

The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on mental component were summed and averaged (range = 0 \[worst\]-100 \[best\]); increase from baseline indicated improvement. If participants' had shown change from baseline in mental health score \>6.33, it was considered as improved; scores between -6.33 to 6.33 was considered unchanged, and score \<-6.33 was considered as worsened. Change from Baseline = difference between the mental component score at Week 24 and the score at Baseline.

Time frame:
From Baseline (Day 1) to Week 24
Reported as:
Number · participants
Number of Participants With Change From Baseline in the Mental Component Scores of SF-36
participantsPlacebo Plus MethotrexateRituximab Plus Methotrexate
Improved40111
Unchanged128144
Worsened2939
SecondaryMean Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score, Genant-modified Sharp Total Score, and Erosion Score

The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290. For all the three radiograph assessment, the minimum score is 0. A higher score indicates more damage and a negative change score indicates improvement. The change in score is to be calculated as: Change from Baseline = difference between the score at Weeks 24, 56, or 104 and the score at Baseline.

Time frame:
From Baseline (Day 1) to Weeks (W) 24, 56, and 104
Reported as:
Mean · units on a scale
Mean Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score, Genant-modified Sharp Total Score, and Erosion Score
units on a scalePlacebo Plus MethotrexateRituximab Plus Methotrexate
Sharp-Genant total score, W24, n = 201, 298-4.3 ± 24.09-1.2 ± 20.90
Sharp-Genant total score, W56, n = 184, 2732.31 ± 5.2831.00 ± 2.751
Sharp-Genant total score, W104, n = 186,2792.82 ± 6.3981.16 ± 3.429
Erosion score, W24, n = 201, 298-1.6 ± 12.15-0.4 ± 10.45
Erosion score, W56, n = 184, 2731.32 ± 3.1550.59 ± 1.843
Erosion score, W104, n = 186,2791.81 ± 4.1870.73 ± 2.262
Joint space narrowing score, W24, n = 201, 298-2.5 ± 12.71-0.9 ± 10.90
Joint space narrowing score, W56, n = 184, 2730.99 ± 2.5710.41 ± 1.323
Joint space narrowing score, W104, n = 186,2791.01 ± 2.6180.43 ± 1.563
SecondaryPercentage of Participants Without Erosive Progression

The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage and negative change score indicates improvement.

Time frame:
Up to Week 104
Reported as:
Number · percentage of participants
Percentage of Participants Without Erosive Progression
percentage of participantsPlacebo Plus MethotrexateRituximab Plus Methotrexate
Baseline to Year 1, n = 186, 2785166
Year 1 to Year 2, n = 186, 2785873
Baseline to Year 2, n = 187, 2814460

Adverse events

Collected over Up to Week 104. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Plus Methotrexate—26/208 (12.5%)152/208 (73.1%)
Rituximab Plus Methotrexate—50/308 (16.2%)225/308 (73.1%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventPlacebo Plus MethotrexateRituximab Plus Methotrexate
Rheumatoid arthritisMusculoskeletal and connective tissue disorders5/2086/308
PneumoniaInfections and infestations0/2083/308
Myocardial infarctionCardiac disorders1/2083/308
Deep vein thrombosisVascular disorders1/2083/308
HypertensionVascular disorders1/2083/308
FallInjury, poisoning and procedural complications2/2080/308
OsteoarthritisMusculoskeletal and connective tissue disorders0/2082/308
CellulitisInfections and infestations0/2082/308
DiverticulitisInfections and infestations0/2082/308
Escherichia urinary tract infectionInfections and infestations0/2082/308
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlacebo Plus MethotrexateRituximab Plus Methotrexate
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders87/208106/308
Upper Respiratory Tract infectionInfections and infestations17/20836/308
HeadacheNervous system disorders21/20831/308
NasopharyngitisInfections and infestations15/20830/308
DiarrhoeaGastrointestinal disorders18/20821/308
HypertensionVascular disorders12/20826/308
BronchitisInfections and infestations15/20825/308
ArthralgiaMusculoskeletal and connective tissue disorders8/20824/308
NauseaGastrointestinal disorders8/20823/308
Urinary Tract InfectionInfections and infestations15/20821/308

Baseline characteristics

Safety population included participants who were randomized and received any part of an infusion of the study drug.

Age, Continuous
Age, Continuous(years)Placebo Plus MethotrexateRituximab Plus MethotrexateTotal
Median55.0 (20 to 79)53.0 (20 to 81)53.0 (20 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Plus MethotrexateRituximab Plus MethotrexateTotal
Female168251419
Male405797
08

Study locations

115 sites
  • Birmingham, Alabama 35294, United States
  • Mesa, Arizona 85208, United States
  • Paradise Valley, Arizona 85253, United States
  • Tucson, Arizona 85724, United States
  • Little Rock, Arkansas 72205, United States
  • Fullerton, California 92835, United States
  • La Jolla, California 92037, United States
  • Los Angeles, California 90045, United States
  • Los Angeles, California 90048, United States
  • Palo Alto, California 94304, United States
  • Pasadena, California 91105, United States
  • Rancho Mirage, California 92270, United States
  • Santa Maria, California 93454, United States
  • Upland, California 91786, United States
  • Danbury, Connecticut 06810, United States
  • Boca Raton, Florida 33486, United States
  • Delray Beach, Florida 33484, United States
  • Fort Lauderdale, Florida 33334, United States
  • Jupiter, Florida 33458, United States
  • Largo, Florida 33773, United States
  • Orlando, Florida 32806, United States
  • Boise, Idaho 83702, United States
  • Coeur D'alene, Idaho 83814, United States
  • Meridian, Idaho 83642, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60637, United States
  • Indianapolis, Indiana 46202-5149, United States
  • Indianapolis, Indiana 46260, United States
  • Shreverport, Louisiana 71103, United States
  • Baltimore, Maryland 21224, United States
  • Boston, Massachusetts 02215, United States
  • Kalamazoo, Michigan 49048, United States
  • Lansing, Michigan 48910, United States
  • Rochester, Minnesota 55905, United States
  • Saint Louis, Missouri 63141, United States
  • St Louis, Missouri 63110, United States
  • Albany, New York 12206, United States
  • Manhasset, New York 11030, United States
  • New York, New York 10003, United States
  • Rochester, New York 14618, United States
  • Smithtown, New York 11787, United States
  • Chapel Hill, North Carolina 27599-7600, United States
  • Durham, North Carolina 27710, United States
  • Greenville, North Carolina 27834, United States
  • Cincinnati, Ohio 45267-0563, United States
  • Cleveland, Ohio 44195, United States
  • Dayton, Ohio 45402, United States
  • Mayfield, Ohio 44143, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Oklahoma City, Oklahoma 73109, United States
  • Tulsa, Oklahoma 74135, United States
  • Duncansville, Pennsylvania 16635, United States
  • Philadelphia, Pennsylvania 19140, United States
  • Philadelphia, Pennsylvania 19141, United States
  • Philadelphia, Pennsylvania 19152, United States
  • Amarillo, Texas 79124, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77074, United States
  • Waco, Texas 76708, United States
  • Salt Lake City, Utah 84132, United States
  • Burlington, Vermont 05401, United States
  • Seattle, Washington 98101, United States
  • Seattle, Washington 98104, United States
  • Spokane, Washington 99204, United States
  • Madison, Wisconsin 53717, United States
  • Madison, Wisconsin 53792, United States
  • Bruxelles, 1070, Belgium
  • Bruxelles, 1200, Belgium
  • Gent, 9000, Belgium
  • Liege, 4000, Belgium
  • Calgary, Alberta T2N 4Z6, Canada
  • Edmonton, Alberta T6G 2S2, Canada
  • Vancouver, British Columbia V5Z 1L7, Canada
  • Hamilton, Ontario L8N 2B6, Canada
  • London, Ontario N6A 4V2, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M5G 1X5, Canada
  • Le Kremlin Bicetre, 94275, France
  • Montpellier, 34295, France
  • Paris, 75679, France
  • Rouen, 76031, France
  • Strasbourg, 67098, France
  • Toulouse, 31059, France
  • Tours, 37044, France
  • Berlin, 10117, Germany
  • Dresden, 01067, Germany
  • Leipzig, 04103, Germany
  • Ratingen, 40882, Germany
  • Wuerzburg, 97080, Germany
  • Cork, Ireland
  • Dublin, 4, Ireland
  • Haifa, 3109601, Israel
  • Haifa, 3339419, Israel
  • Jerusalem, 9112001, Israel
  • Petach Tikva, 4941492, Israel
  • Ramat Gan, 5262000, Israel
  • Tel Aviv, 6423906, Israel
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Arenzano, Liguria 16011, Italy

Showing the first 100 of 115 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum. 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596. PubMed 22127691 ↗
  • Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, Tak PP, Broder MS, Yu E, Cravets M, Magrini F, Jost F. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008 Jun 15;59(6):785-93. doi: 10.1002/art.23715. PubMed 18512710 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Jan 2005 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 11 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2007
First posted
May 2, 2007
Start
May 2003
Primary completionActual
Jan 2005
CompletionActual
Jul 2012
Results first posted
Oct 25, 2016
Last update
Oct 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00468546
Lead sponsor
Hoffmann-La Roche
Collaborators
Biogen
Responsible party
Sponsor
First posted
May 2, 2007
Start date
May 2003
Primary completion
Jan 2005
Completion
Jul 2012
Results posted
Oct 25, 2016
Last update
Oct 25, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion